⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of TORL BioTherapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
TORL BioTherapeutics
↗Culver City, United States
TORL BioTherapeutics is a privately held, clinical-stage oncology biotechnology company developing antibody-based cancer therapies, with a focus on antibody-drug conjugates and monoclonal antibodies directed at tumor-associated molecular targets. The company was built around a strategic research relationship with the Slamon Research Laboratory at UCLA and holds exclusive development and commercialization rights to a portfolio of biologics-based drug candidates targeting antigens overexpressed in cancer cells. ([torlbio.com](https://torlbio.com/))
TORL's most advanced program is ixotatug vedotin, also called Ixo-V or TORL-1-23, a CLDN6-targeted ADC being evaluated in ovarian and other CLDN6-positive solid tumors. The company is advancing a registrational Phase 2 program in platinum-resistant ovarian cancer, additional ovarian-cancer combinations, a Phase 1 hematology program, and earlier or previously clinical-stage programs targeting CLDN18.2, CDH17 and DLK1. TORL reported more than $450 million in total financing by October 2025 and remains focused on advancing multiple oncology assets toward potential regulatory filings. ([prnewswire.com](https://www.prnewswire.com/news-releases/torl-biotherapeutics-secures-96m-series-c-financing-and-presents-updated-phase-1-results-of-novel-claudin-6-targeted-antibody-drug-conjugate-torl-1-23-at-the-2025-european-society-of-medical-oncology-congress-302576530.html))
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:More than $450M
Investors:Deep Track Capital, RA Capital Management, Perceptive Advisors, Avidity Partners, Goldman Sachs Alternatives / Goldman Sachs Asset Management, UC Investments / University of California Office of the Chief Investment Officer, Bristol Myers Squibb, Vertex Ventures HC, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Perceptive Xontogeny Venture Fund, Alexandria Venture Investments, OCV Partners, Cowen Healthcare Investments
PIPELINE
Stage:Phase 2 lead program with multiple Phase 1 and earlier-stage oncology assets
Lead Drug Stage:Phase 2 registrational / registration-enabling
Modalities:Antibody-drug conjugates, Monoclonal antibodies, Targeted biologics, Companion-diagnostic-linked therapies
Active Trials:6
Trial Phases:Phase 1: 4 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Slamon Research Laboratory and UCLA: strategic research partnership providing access to cancer-target discovery, antibody development and exclusive development/commercialization rights to a portfolio of biologics. ([torlbio.com](https://torlbio.com/)), Translational Research in Oncology: clinical-development collaborator on multiple TORL-sponsored Phase 1 studies. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05103683?utm_source=openai)), Global oncology research networks and clinical sites, including Sarah Cannon Research Institute and major academic cancer centers, supporting multinational trials. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05103683?utm_source=openai))
COMPETITION
Position:Emerging
Competitors:BioNTech, including CLDN6-directed BNT211 cell-therapy programs, Context Therapeutics, including CLDN6-directed CTIM-76 T-cell engager programs, Astellas Pharma, including CLDN6-targeted oncology development, AstraZeneca, including CLDN18.2 and broader ADC programs, Zymeworks, including gastrointestinal-cancer antibody and ADC programs, Sutro Biopharma, including next-generation ADC oncology programs, I-Mab and other CLDN18.2-focused antibody developers, Mabwell and other China-based CLDN18.2 and ADC developers
LEADERSHIP
Key Executives:
Aran Maree, MD - Chief Executive Officer, Chief Medical Officer and Director
Dave Licata - Chief Financial Officer, Chief Technology Officer, Director and Co-Founder
Christine Loggins - Chief Operating Officer
Steve Ritland, PhD - Chief Scientific Officer
Vince Ruiz, JD - General Counsel
Donna Schubert, PhD - Senior Vice President, Quality
Nora Ku, MD - Senior Vice President, Medical Sciences
Adrine Kung - Senior Vice President, Development Strategy and Planning
Kamala Lakamsani - Vice President, Companion Diagnostics
Mark Alles - Chairman
Scientific Founders:Dennis Slamon, MD, PhD, Neil O'Brien, PhD, Dave Licata, John Glaspy, MD, MPH, Martina McDermott, PhD, Ben Hoffstrom, PhD, Sarah Larson, MD, Michael Press, MD, PhD
Board Members:Mark Alles — Chairman, Aran Maree, MD — CEO and Director, Dave Licata — Director and Co-Founder, Mark Attanasio — Director; Co-Founder and Managing Partner, Crescent Capital, Anna Berkenblit, MD, MMSc — Director; Chief Scientific and Medical Officer, PanCAN, Howard A. "Skip" Burris III, MD — Independent Director; President and Chief Medical Officer, Sarah Cannon Research Institute, Neil O'Brien, PhD — Director and Co-Founder; Associate Professor, UCLA, Amit Sinha — Director; CIO, Goldman Sachs Life Sciences, Dennis Slamon, MD, PhD — Director and Co-Founder; Chief of Hematology-Oncology, UCLA
LINKS
Website:torlbio.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with TORL BioTherapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.